Data analysis could , for instance , show that the combination of headaches , nausea and lethargy equates to a specific type of bleeding disorder . " You can start to put these things in categories ", Easton says . " And then you ' re able to do differential diagnosis . But ultimately , what you ' re trying to do is get a faster , more accurate diagnosis , leading to a specific therapy ."
This would be more efficient than administering plasma-based treatments , for example . " A lot of bleeding disorders are caused by a deficiency of something ", Easton explains . " There is a lot of combination therapy in blood disorders when you give people plasma-based products because plasma is like the golden chalice of medicine . It has a bit of everything you need . In some cases , when you don ' t know what the disorder is , this can help patients , but it ' s not the most precise way of doing it ."
" That ' s one of the ways having very clear diagnostic support linked to advanced direct therapy can help , only treating what you need to . From a payer ' s perspective , it ' s very targeted , and there ' s no wasting money and resources on patients being hospitalised for things that are not necessary ."
" If you go back 15-20 years , market access to the pharmaceutical industry was the emerging trend ", Easton adds . " We saw all these diagrams of physician decision-making coming down and payer decision-making going up . Now we have another divergence of change , which is the application of technology to support personalised care . This is one of the transformative pieces of pharma right now , and there are a lot of good companies , big and small , being very intelligent about how they ' re approaching it and investing in those spaces . There ' s definitely a community building ."
healthcareglobal . com 125